clinical trial · NCT05878769
A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
Hoffmann-La Roche·phase3·recruiting·n = 2,000
Chronic Obstructive Pulmonary DiseaseAstegolimab
brief summary
The purpose of this study is to assess the long-term safety and to explore the efficacy of astegolimab in participants with chronic obstructive pulmonary disease (COPD) who have completed the 52-week placebo-controlled treatment period in parent studies GB43311 or GB44332.
started
Jun 28, 2023
primary completion
Jun 30, 2027
completion
Jun 30, 2027
last updated
Apr 2, 2026
official title
A Phase III Open-Label Extension Study to Evaluate the Long-Term Safety of Astegolimab in Patients With Chronic Obstructive Pulmonary Disease
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol